33 years after the first approval of a monoclonal antibody for therapeutic use, the biopharmaceutical industry has close to 100 therapeutic monoclonal antibodies approved or in review in the EU or the US, many of which use highly similar purification platforms.  Meanwhile, we have seen a rise in new powerful therapeutic modalities that offer possibility of permanent cures for serious diseases and reduced dosing frequency.  As such, a relevant question would be: “Is there really more we need to do with monoclonal antibody purification?”.  The short answer is yes.  This keynote presentation will discuss current challenges as well as future trends in the purification of therapeutic monoclonal antibodies for human use.

Current and future challenges in monoclonal antibody purification

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.